Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Dave Stirling - Vice President, Small Molecule Pharmaceutical Sciences

Dave Stirling

Vice President, Small Molecule Pharmaceutical Sciences

"My personal mission is to fully integrate development and translational efforts into the drug discovery and use the most contemporary approaches to bring new medicines to patients with an sense of urgency"
Years at Genentech

I joined Genentech in November of 2005 to build a Small Molecule Pharmaceutical Sciences group. Our group is responsible for delivering clinical supplies to the clinic and developing a robust and scalable manufacturing process, including the controls to ensure quality products for our patients. The Small Molecule Pharmaceutical Sciences group consists of three major disciplines: Process Chemistry, Formulation Development, and Analytical Development. We have created a unique CMC group that is fully integrated with drug discovery and fueled by an entrepreneurial culture.

I was attracted to Genentech because of their commitment to basic research, high quality science, and ability to translate this knowledge into drugs designed to meet patient needs. I am excited to be a part of the small molecule discovery and development effort and working with top scientists who share the same passion for innovation and sense of urgency.